1[1]Ceburkov O, Gollnick H. Photodynamic therapy in dermatology[J].Eur J Dermatol, 2000, 10(7): 568-576.
2[2]Lange N, Jichlinski P, Zellweger M, et 1. Photodetection of early human bladder cancer based on the fluorescence of 5-aminolaevulinic acid hexylester-induced protoporphyrin IX: a pilot study[J] . Br J Cancer, 1999, 80(1-2): 185-193.
3[3]Fritsch C, Goerz G, Ruzicka T. Photodynamic therapy in dermatology[J]. Arch Dermatol, 2000, 10: 568-576.
4[4]Bunke A, Zerbe O, Schmid H, et al. Degradation mechanism and stability of 5-aminolevulinic acid[J] . J Pharm Sci, 2000, 89(10):1335-1341.
5[5]Soler AM, Warloe T, Tausjo, J, et al. Photodynamic therapy of residual or recurrent basal cell carcinoma after radiotherapy using topical 5-aminolevulinic acid or methylester aminolevulinic acid[J] . Acta Oncol, 2000, 39(5): 605-609.
6[6]Szeimies RM, Karrer S, Sauerwald A, et al. Photodynamic therapy with topical application of 5-aminolevulinic acid in the treatment of actinic keratoses: an initial clinical study[J]. Dermatology, 1996, 192 (3)246-251.
7[7]Kurwa HA, Yong-Gee SA, Seed PT, et al. A randomized paired comparison of photodynamic therapy and topical 5-fluorouracil in the treatment of actinic keratoses[J] . J Am Acad Dermatol, 1999, 41 (3Ptl): 414-418.
8[8]Salim A, Whitehurst C, Morton CA. Comparison of photodynamic therapy with cryotherapy in the treatmen of Bowen' s disease[J]. Br J of Dermatol, 2000, 114(Suppl. 57): 114.
9[9]Morton CA, Whitehurst C, Mccoll JH, et al. Photodynamic therapy for large or multiple patches of Bowen' s disease and basal cell carcinoma[J]. Arch Dermatol, 2001, 137(3): 319-324,
